What it's for (Indications)
- This combination topical medication, comprising betamethasone, mupirocin, and miconazole, is broadly indicated for the localized treatment of inflammatory dermatological conditions where concomitant bacterial and fungal infections are present or highly suspected.
- Betamethasone, a potent corticosteroid, effectively addresses inflammation, pruritus, and erythema.
- Mupirocin, an antibiotic, targets susceptible Gram-positive bacteria, including *Staphylococcus aureus* (e.
- g.
- , MRSA) and *Streptococcus pyogenes* resistant strains.
- Miconazole, an antifungal agent, is active against a wide spectrum of dermatophytes and yeasts, such as *Candida albicans*.
- The synergistic action of these three components aims to manage complex skin conditions characterized by mixed etiologies, providing comprehensive symptomatic relief and pathogen eradication when appropriate diagnostic evaluation confirms the presence of all targeted components.
- This formulation is often considered when monotherapy with an antifungal, antibacterial, or corticosteroid alone is insufficient to control symptoms or eliminate infection.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The precise dosage, frequency, and duration of application for this compounded topical formulation must be individually determined by a qualified healthcare provider based on the patient's specific condition, severity, and the size and location of the treated area. Generally, a thin layer of the ointment is applied to the affected skin area two to three times daily, or as directed by the prescribing physician. It is crucial to use the minimum effective amount for the shortest necessary duration to minimize potential systemic absorption and localized side effects, particularly those associated with the corticosteroid component. Patients should be explicitly instructed on the application technique, emphasizing gentle massage until absorbed, and to avoid occlusive dressings unless specifically advised by their physician, as occlusion can significantly increase systemic absorption of betamethasone. Adherence to the prescribed regimen is vital for optimal therapeutic outcomes and to mitigate risks of resistance or adverse events. |
Safety & Warnings
Common Side Effects
- As with any potent topical medication, this combination ointment can induce various side effects, primarily localized to the application site.
- Common dermatological reactions may include burning, stinging, itching, irritation, redness, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
- Due to the betamethasone component, prolonged or extensive use, especially under occlusion or on large surface areas, can lead to systemic effects such as hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria.
- Mupirocin may cause localized burning or itching at the application site.
- Miconazole may cause irritation, burning, or sensitivity reactions.
- Patients should promptly report any persistent or worsening adverse reactions, signs of systemic effects, or indications of allergic reactions to their healthcare provider for evaluation.
Serious Warnings
- Black Box Warning: Serious Warnings: This product, containing a potent corticosteroid (betamethasone), an antibiotic (mupirocin), and an antifungal (miconazole), lacks a formal FDA Black Box Warning as a compounded combination. However, serious warnings are warranted due to the inherent risks associated with its active components. **Systemic Absorption Risk:** Prolonged use, application to large surface areas, use under occlusive dressings, or use in children can lead to significant systemic absorption of betamethasone. This can result in reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria. Discontinuation of treatment should be gradual if HPA axis suppression is suspected. **Risk of Infection Exacerbation/Masking:** The corticosteroid component can mask signs of infection, potentially leading to worsening or spread of bacterial, fungal, or viral pathogens if not adequately controlled by the antimicrobial agents, or if inappropriate for the pathogen. **Antibiotic Resistance:** Indiscriminate or prolonged use of mupirocin can contribute to the development of bacterial resistance, limiting its future efficacy and potentially impacting public health. This formulation should only be used when a mixed infection requiring all three components is clearly diagnosed or strongly suspected, for the shortest duration necessary, and under strict medical supervision to mitigate these significant risks.
- This combination product should be used with extreme caution, particularly regarding the potent corticosteroid component, betamethasone.
- Prolonged or extensive use, application to large surface areas, use under occlusive dressings, or application to intertriginous areas can lead to significant systemic absorption of the corticosteroid, potentially causing reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria.
- Pediatric patients may be more susceptible to systemic toxicity due to a larger skin surface area to body weight ratio and underdeveloped skin barrier function.
- Treatment should be discontinued if irritation, sensitization, or superinfection develops.
- Appropriate antimicrobial therapy must be initiated if co-existing viral infections are present, as corticosteroids can exacerbate them.
- The mupirocin component carries a risk of inducing bacterial resistance if used indiscriminately or for prolonged periods, necessitating judicious use based on confirmed bacterial etiology.
- Avoid contact with eyes, mucous membranes, and open wounds.
- This medication is for external use only and should not be ingested.
- The efficacy and safety for use in pregnant or breastfeeding individuals require careful risk-benefit assessment by a healthcare professional, considering potential systemic absorption of all components.
How it Works (Mechanism of Action)
This tripartite topical formulation exerts its therapeutic effects through the distinct mechanisms of its active constituents. **Betamethasone**, a potent synthetic corticosteroid, acts primarily as an anti-inflammatory, antipruritic, and vasoconstrictive agent. It functions by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. This suppresses the inflammatory cascade at multiple levels. **Mupirocin**, an antibiotic, inhibits bacterial protein synthesis by reversibly binding to bacterial isoleucyl-tRNA synthetase, an enzyme crucial for the incorporation of isoleucine into bacterial proteins. This unique mechanism reduces the likelihood of cross-resistance with other antimicrobial classes and is particularly effective against Gram-positive bacteria, including methicillin-resistant *Staphylococcus aureus* (MRSA). **Miconazole**, an azole antifungal, acts by inhibiting the biosynthesis of ergosterol, a vital component of fungal cell membranes. This inhibition leads to structural and functional damage to the fungal cell membrane, resulting in increased permeability, leakage of cellular contents, and ultimately, fungal cell death. The combined action provides comprehensive treatment for inflammatory dermatoses complicated by susceptible bacterial and fungal pathogens by simultaneously targeting inflammation, bacteria, and fungi.
Commercial Brands (Alternatives)
No other brands found for this formula.